Journal profile · Immunology
Immunotherapy
ISSN 1750-743X · eISSN 1750-7448 · TAYLOR & FRANCIS LTD · ENGLAND · Bimonthly
Immunotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.42; hybrid open access; APC charged, amount not published; median 109 days to acceptance (100 articles, last 24 months); community-reported acceptance: fairly easy; 135 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Immunotherapy is published by TAYLOR & FRANCIS LTD and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and CAR-T cell therapy research, together about 44.9% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Immunotherapy is a subscription-based peer-reviewed journal covering both preclinical research and clinical research, as well as the applications of immunotherapy. The journal’s audience includes researchers and clinicians interested in immunotherapy for cancers and other diseases. Journal coverage includes key areas such as: • Cancer immunotherapy, including checkpoint blockade, cancer vaccines, adoptive T cell therapy, monoclonal antibodies and cytokines • Combined chemo/radio immunotherapy in cancer treatment • Biomarkers for personalized cancer immunotherapy • Allergen immunotherapy, including sublingual, subcutaneous and oral immunotherapy • Restorative immunotherapy for HIV and other immunocompromised patients • Suppressive immunotherapy for autoimmunity diseases and transplantation • Basic science of immunotherapeutic approaches • Drug–immune system interactions • Drug delivery systems, drug combinations and drug–drug interactions • Summaries evaluating newly approved immunotherapeutic agents • Newly identified immune targets of drugs • Results of recent findings and clinical trials relevant to the field of immunotherapy • Post marketing research, including adverse events, drug safety, pharmacoeconomics, cost–benefit issues, real-world evidence and outcomes research The journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Original Research Articles, Reviews. All articles received by the journal will be subject to double-anonymous peer review. Please note that this journal does not publish original research without in vivo work. Authors can choose to publish gold open access in this journal. Please read the Instructions for Authors for information on how to submit your article.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editorial board by country: none in mainland China; most named United Kingdom 2, United States 1, Japan 1 (4 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine18.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology15.4%
- CAR-T cell therapy researchMedicine10.6%
- Immune Cell Function and InteractionImmunology and Microbiology10.4%
- T-cell and B-cell ImmunologyImmunology and Microbiology3.9%
- Allergic Rhinitis and SensitizationMedicine3.9%
- Monoclonal and Polyclonal Antibodies ResearchMedicine3.8%
- Asthma and respiratory diseasesMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Index Medicus, Biological Abstracts, BIOSIS Previews, Essential Science Indicators, Journal Citation Reports/Science Edition, Research Alert
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.42LetPub ·
- Impact factor (publisher) 2025
- 2.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.3Publisher website ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher) 2025
- 4.2Publisher website ·
- SJR 2026-06
- 0.67LetPub ·
- SJR (publisher) 2025
- 0.67Publisher website ·
- SNIP 2026-06
- 0.53LetPub ·
- SNIP (publisher) 2025
- 0.53Publisher website ·
- h-index
- 37LetPub ·
- h-index
- 83OpenAlex ·
- i10-index
- 1,088OpenAlex ·
- 2-year mean citedness
- 2.51OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 10%LetPub ·
Volume
- Articles per year
- 104LetPub ·
- Downloads per year (publisher)
- 296,000Publisher website ·
Articles by year OpenAlex count · 2,429 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 81 | 73 | 22 |
| 2025 | 135 | 125 | 341 |
| 2024 | 106 | 84 | 446 |
| 2023 | 159 | 41 | 1,071 |
| 2022 | 117 | 33 | 1,358 |
| 2021 | 147 | 41 | 1,766 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
109 daysMedian, submission to acceptance · P25–P75 79 days – 151 days
- Acceptance to online
- median 8 days (100 articles)
- Submission to online
- median 119 days
- Sample
- 100 articles with submission and acceptance dates (238 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 25%Publisher website ·
- Submission to first decision
- 20 daysPublisher website ·
- First decision after review
- 66 daysPublisher website ·
- Acceptance to publication
- 8 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted7
- case reports/seriesThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- clinical trial protocolsThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- drug evaluationsThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- editorialsThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- original research articlesThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- plain language summariesThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
- reviewsThe journal welcomes for consideration the following: Case Reports/Series, Clinical Trial Protocols, Drug Evaluations, Editorials, Plain Language Summaries, Ori…Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review, Preprints
- Open access Open access
Immunotherapy is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readershi…
Source ↗Publisher website ·- Peer review
All articles received by the journal will be subject to double-anonymous peer review. Model summary
All articles received by the journal will be subject to double-anonymous peer review.
Source ↗Publisher website ·- Preprints
This journal does not publish original research without in vivo work. Model summary
Please note that this journal does not publish original research without in vivo work.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- TAYLOR & FRANCIS LTD
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1750-743X
- Electronic ISSN
- 1750-7448
- Latest issue on the website
- Volume 18, Issue 10 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Immunotherapy
What CAS zone is Immunotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Immunotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Immunotherapy?
The latest impact factor listed by LetPub is 2.42; CiteScore 4.2, h-index 83.
How long does peer review take at Immunotherapy?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 79–151 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 25%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Immunotherapy based?
Of the 4 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (2), United States (1) and Japan (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Immunotherapy?
According to LetPub and DOAJ records, Immunotherapy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Immunotherapy open access, and what is the APC?
Immunotherapy is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .